单克隆抗体的临床药理动力学的抗体间变异性,使用基于人群生理学的药理动力学建模来表征
Mokshada Kumar1, Sravani Lanke1, Alka Yadav1
1Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, NY 14214-8033, USA.
一个新的基于人群生理学的药理动力学 (popPBPK) 模型预测单克隆抗体 (mAb) 临床PK. 这种工具有助于预测mAb的处置,并优化新抗体疗法的首次人体剂量.
科学领域:
- 药理动力学和药理动力学
- 生物技术是生物技术.
- 药物开发 药物开发
背景情况:
- 单克隆抗体 (mAbs) 显示出显著的药理动力学 (PK) 变异性.
- 预测mAb临床PK对于有效的治疗开发和安全的剂量至关重要.
- 现有的模型可能无法完全捕捉个人间和抗体间的变异性.
研究的目的:
- 为单克隆抗体 (mAbs) 开发一个基于人群生理学的药理动力学 (popPBPK) 模型.
- 在静脉 (IV) 和皮下 (SC) 给药后,对mAb临床PK的变异性进行表征.
- 建立一个用于预测mAb PK和支持早期临床开发的工具.
主要方法:
- 收集了批准和未批准的mAbs. 的临床PK数据.
- 使用训练 (44 mAbs) 和验证 (9 mAbs) 数据集开发了一个popPBPK模型.
- 嵌入的变异性在pinocytosis,细胞内降解,局部SC降解和淋巴吸收率.
主要成果:
- 关键PK参数 (CLup, kdeg, kSC, S_Lu) 的估计典型值和抗体间的变异性.
- 与其他药物相比,FDA批准的mAbs观察到较少的局部降解.
- 通过准确预测九个独立的mAbs的PK,验证了popPBPK模型.
结论:
- 开发的popPBPK模型有效地描述了mAb PK的变性.
- 该模型可以预测具有线性配置的mAbs的临床PK.
- 该工具支持临床前转化为临床转化以及对mAbs.mAbs.的"首次在人体"剂量选择.
更多相关视频
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
10:50Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
Published on: May 1, 2019
相关概念视频
Analysis of Population Pharmacokinetic Data
Physiological Pharmacokinetic Models: Assumption with Protein Binding
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
